Skip to content
HowShorted

Neurogene Inc. short interest in 2018

In 2018, Neurogene Inc.'s disclosed short interest ran from 1.12% of shares outstanding on 12 Jan 2018 to 0.99% on 31 Dec 2018, a change of -0.13 percentage points. The year's high was 3.19% on 29 Jun 2018 and its low 0.64% on 30 Nov 2018, averaging 1.35% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.89 days on 15 Jun 2018. Full history: Neurogene Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Neurogene Inc. in 2018

2018 in figures

Start of year
1.12% (12 Jan 2018)
End of year
0.99% (31 Dec 2018)
Change
-0.13 pp
High
3.19% (29 Jun 2018)
Low
0.64% (30 Nov 2018)
Average
1.35%
Highest days to cover
4.89 (15 Jun 2018)
SEC filings marked
8

Every report in 2018

Neurogene Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20181.12%3.83
31 Jan 20181.17%2.57
15 Feb 20181.36%1.71
28 Feb 20181.40%2.51
15 Mar 20181.29%2.9410-K filed, results (8-K)
29 Mar 20181.29%3.66
13 Apr 20181.05%2.99
30 Apr 20181.13%4.66
15 May 20181.25%3.9010-Q filed, results (8-K)
31 May 20181.68%3.42
15 Jun 20182.31%4.89
29 Jun 20183.19%1.00
31 Jul 20182.12%1.00
15 Aug 20181.33%1.0010-Q filed, results (8-K)
31 Aug 20180.90%1.00
14 Sep 20181.45%1.64
28 Sep 20181.48%2.12
15 Oct 20181.52%1.89
31 Oct 20180.83%1.43
15 Nov 20180.85%1.9910-Q filed, results (8-K)
30 Nov 20180.64%1.00
14 Dec 20180.72%2.28
31 Dec 20180.99%2.05

See also: Neurogene Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.